Diasome's HDV-Insulin demonstrates substantial Level 2 hypoglycemia reductions in setting of increased insulin use
The OPTI-1 trial shows increasing liver-targeted bolus insulin restores liver physiology allowing subjects to decrease Level 2 hypoglycemia by 50% at nighttime CLEVELAND, OH, UNITED STATES , June 2, 2022 /EINPresswire.com/ -- Diasome Pharmaceuticals, …